144 related articles for article (PubMed ID: 29983705)
1. Exploration on the Interaction Ability of Antitumor Compound Bis-[2,6-difluoro-
Mai J; Li Y; Qiao X; Ji X; Li Q
Bioinorg Chem Appl; 2018; 2018():3063271. PubMed ID: 29983705
[TBL] [Abstract][Full Text] [Related]
2. Diorganotin(IV) derivatives of substituted N-hydroxybenzamides with selective cytotoxicity in vitro and potent antitumor activity in vivo.
Li YL; Wang ZW; Guo P; Tang L; Ge R; Ban SR; Chai QY; Niu L; Li QS
J Inorg Biochem; 2014 Apr; 133():1-7. PubMed ID: 24413257
[TBL] [Abstract][Full Text] [Related]
3. Spectroscopic studies and molecular docking on the interaction of organotin antitumor compound bis[2,4-difluoro-N-(hydroxy-⟨κ⟩O)benzamidato-⟨κ⟩O]diphenyltin(IV) with human cytochrome P450 3A4 protease.
Wei Y; Niu L; Liu X; Zhou H; Dong H; Kong D; Li Y; Li Q
Spectrochim Acta A Mol Biomol Spectrosc; 2016 Jun; 163():154-61. PubMed ID: 27049867
[TBL] [Abstract][Full Text] [Related]
4. Structural Biology Inspired Development of a Series of Human Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) Ligands: From Agonist to Antagonist.
Miyachi H
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835351
[TBL] [Abstract][Full Text] [Related]
5. Molecular dynamics study-guided identification of cyclic amine structures as novel hydrophobic tail components of hPPARγ agonists.
Tanaka Y; Gamo K; Oyama T; Ohashi M; Waki M; Matsuno K; Matsuura N; Tokiwa H; Miyachi H
Bioorg Med Chem Lett; 2014 Aug; 24(16):4001-5. PubMed ID: 25017035
[TBL] [Abstract][Full Text] [Related]
6. Different structures of the two peroxisome proliferator-activated receptor gamma (PPARγ) ligand-binding domains in homodimeric complex with partial agonist, but not full agonist.
Ohashi M; Oyama T; Miyachi H
Bioorg Med Chem Lett; 2015 Jul; 25(13):2639-44. PubMed ID: 25987371
[TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptor gamma (PPARγ) has multiple binding points that accommodate ligands in various conformations: Structurally similar PPARγ partial agonists bind to PPARγ LBD in different conformations.
Ohashi M; Gamo K; Oyama T; Miyachi H
Bioorg Med Chem Lett; 2015 Jul; 25(14):2758-62. PubMed ID: 26025876
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic flavonoids as agonists of peroxisome proliferator-activated receptor gamma on human cervical and prostate cancer cells.
Lee JY; Kim JK; Cho MC; Shin S; Yoon DY; Heo YS; Kim Y
J Nat Prod; 2010 Jul; 73(7):1261-5. PubMed ID: 20583750
[TBL] [Abstract][Full Text] [Related]
9. Establishment of a cell-based drug screening model for identifying agonists of human peroxisome proliferator-activated receptor gamma (PPARγ).
Ma JJ; Zhang T; Fang N; Zou Y; Gong QH; Yu LM; Chen DX
J Pharm Pharmacol; 2012 May; 64(5):719-26. PubMed ID: 22471368
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of a series of α-benzyl phenylpropanoic acid-type peroxisome proliferator-activated receptor (PPAR) gamma partial agonists with improved aqueous solubility.
Ohashi M; Oyama T; Putranto EW; Waku T; Nobusada H; Kataoka K; Matsuno K; Yashiro M; Morikawa K; Huh NH; Miyachi H
Bioorg Med Chem; 2013 Apr; 21(8):2319-2332. PubMed ID: 23490155
[TBL] [Abstract][Full Text] [Related]
11. Structure-dependent binding and activation of perfluorinated compounds on human peroxisome proliferator-activated receptor γ.
Zhang L; Ren XM; Wan B; Guo LH
Toxicol Appl Pharmacol; 2014 Sep; 279(3):275-283. PubMed ID: 24998974
[TBL] [Abstract][Full Text] [Related]
12. Substitution of a conserved amino acid residue alters the ligand binding properties of peroxisome proliferator activated receptors.
Causevic M; Wolf CR; Palmer CN
FEBS Lett; 1999 Dec; 463(3):205-10. PubMed ID: 10606722
[TBL] [Abstract][Full Text] [Related]
13. Organotin(IV) complexes derived from Schiff base N'-[(1E)-(2-hydroxy-3-methoxyphenyl)methylidene]pyridine-4-carbohydrazone: synthesis, in vitro cytotoxicities and DNA/BSA interaction.
Hong M; Geng H; Niu M; Wang F; Li D; Liu J; Yin H
Eur J Med Chem; 2014 Oct; 86():550-61. PubMed ID: 25216377
[TBL] [Abstract][Full Text] [Related]
14. Interspecies Differences in Activation of Peroxisome Proliferator-Activated Receptor γ by Pharmaceutical and Environmental Chemicals.
Garoche C; Boulahtouf A; Grimaldi M; Chiavarina B; Toporova L; den Broeder MJ; Legler J; Bourguet W; Balaguer P
Environ Sci Technol; 2021 Dec; 55(24):16489-16501. PubMed ID: 34843233
[TBL] [Abstract][Full Text] [Related]
15. In silico approach for the discovery of new PPARγ modulators among plant-derived polyphenols.
Encinar JA; Fernández-Ballester G; Galiano-Ibarra V; Micol V
Drug Des Devel Ther; 2015; 9():5877-95. PubMed ID: 26604687
[TBL] [Abstract][Full Text] [Related]
16. cis-parinaric acid is a ligand for the human peroxisome proliferator activated receptor gamma: development of a novel spectrophotometric assay for the discovery of PPARgamma ligands.
Palmer CN; Wolf CR
FEBS Lett; 1998 Jul; 431(3):476-80. PubMed ID: 9714568
[TBL] [Abstract][Full Text] [Related]
17. To Probe Full and Partial Activation of Human Peroxisome Proliferator-Activated Receptors by Pan-Agonist Chiglitazar Using Molecular Dynamics Simulations.
Sullivan HJ; Wang X; Nogle S; Liao S; Wu C
PPAR Res; 2020; 2020():5314187. PubMed ID: 32308671
[TBL] [Abstract][Full Text] [Related]
18. Molecular Modeling Study for the Design of Novel Peroxisome Proliferator-Activated Receptor Gamma Agonists using 3D-QSAR and Molecular Docking.
Jian Y; He Y; Yang J; Han W; Zhai X; Zhao Y; Li Y
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29473866
[TBL] [Abstract][Full Text] [Related]
19. Aqua-(benzamidato-κN)bis-[3,5-difluoro-2-(pyridin-2-yl)phenyl-κC]iridium(III) methanol monosolvate.
Zhang S; Wu F; Ding Y
Acta Crystallogr Sect E Struct Rep Online; 2012 Mar; 68(Pt 3):m310. PubMed ID: 22412451
[TBL] [Abstract][Full Text] [Related]
20. Diorganotin(IV) derivatives of N-methyl p-fluorobenzo-hydroxamic acid: preparation, spectral characterization, X-ray diffraction studies and antitumor activity.
Naqeebullah ; Farina Y; Chan KM; Mun LK; Rajab NF; Ooi TC
Molecules; 2013 Jul; 18(7):8696-711. PubMed ID: 23881054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
